NCT03120299 is a Phase 4 clinical trial of Omega-3 fatty acid in Type 2 Diabetes Mellitus, sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT03120299?

NCT03120299 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT03120299?

Interventions in NCT03120299: Omega-3 fatty acid, Placebos.

What condition does NCT03120299 study?

NCT03120299 studies Type 2 Diabetes Mellitus, Hypertriglyceridemia.

Is NCT03120299 still recruiting?

NCT03120299 is currently completed. Last updated 30 October 2023.

Last reviewed 2023-10-30 · How we verify

NCT03120299

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)

Completed Phase 4 Last updated 30 October 2023

What this trial tests

Phase 4 trial testing Omega-3 fatty acid in Type 2 Diabetes Mellitus in 309 participants. Completed in 1 June 2021.

Timeline

1 May 2017

Primary endpoint
1 March 2021

1 June 2021

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	309
Start date	1 May 2017
Primary completion	1 March 2021
Estimated completion	1 June 2021
Sites	1 location across China

Drugs / interventions tested

Omega-3 fatty acid
Placebos — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Hypertriglyceridemia — all drugs for Hypertriglyceridemia →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 20 to 75, any sex, with Type 2 Diabetes Mellitus or Hypertriglyceridemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to conduct a multicenter randomized, double-blind, placebo-controlled clinical trial, evaluating the effects and change of lipid metabolism, especially of triglyceride after omega-3 administration in type 2 diabetes patients with hypertriglyceride.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
Huda MN, Kim M, Bennett BJ. · · 2021 · cited 89× · PMID 33897618 · DOI 10.3389/fendo.2021.632335
Impact of omega-3 fatty acids on hypertriglyceridemia, lipidomics, and gut microbiome in patients with type 2 diabetes.
Lu J, Liu R, Ren H, Wang S, et al · · 2025 · cited 15× · PMID 39163858 · DOI 10.1016/j.medj.2024.07.024

Verify or expand the search:

Other trials of Omega-3 fatty acid

Trials testing the same drug.

NCT05924139 — Omega-3 Fatty Acid Supplementation to Enhance Performance · NA · completed
NCT01821833 — Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel · NA · completed
NCT01881048 — Window of Opportunity Study Targeting the Inflammatory Milieu · EARLY_PHASE1 · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03120299 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 30 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03120299.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing